A generic alternative indicated for Neurology. This preparation supports neuromuscular signal transmission and assists in sustaining muscle strength for improved mobility.
A cholinesterase inhibitor designed to manage muscle weakness in myasthenia gravis and intended to alleviate fatigue to support improved muscle strength and endurance.
Mechanism of Action
It inhibits the enzyme acetylcholinesterase, which breaks down acetylcholine. This allows acetylcholine to accumulate at the junction between nerves and muscles, enhancing signal transmission.
Route of Administration
Oral
Onset Time
30–60 minutes
Duration
3–6 hours
Contraindications
Intestinal obstruction, Urinary tract obstruction, Allergy to bromides, Allergy to pyridostigmine
Severe Adverse Events
Cholinergic crisis, Severe respiratory distress, Seizures, Severe bradycardia
Information for Mestinon is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
